Lithium Ion

Lithium Ion

SCHEMBL9893839

Cc1ccc(Cl)cc1-n1c(C2CCCCC2)nc(C(=O)[O-])c1-c1cccc(Cl)c1.[Li+]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 9/20 0.56
PDE4B Q07343 2/20 0.39
PDE4D Q08499 2/20 0.39
CNR2 P34972 2/20 0.38
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
POLB P06746 1/20 0.37
GRM5 P41594 1/20 0.37
ATM Q13315 1/20 0.37
DRD1 P21728 1/20 0.36
DRD5 P21918 1/20 0.36
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL9893840 0.90 MDM2 (0.68) MDM2PDE4BPDE4DCNR2TP53
SCHEMBL9893838 0.90 MDM2 (0.68) MDM2PDE4BPDE4DCNR2TP53
SCHEMBL9893915 0.90 MDM2 (0.62) MDM2PDE4BPDE4DCNR2TP53
Lithium Ion SCHEMBL9894072 0.88 MDM2 (0.61) MDM2PDE4BPDE4DCNR2
Acetamide SCHEMBL27862825 0.87 MDM2 (0.64) MDM2PDE4BPDE4DCNR2TP53
SCHEMBL1437051 0.86 MDM2 (0.56) MDM2PDE4BPDE4DALDH1A1
SCHEMBL9894130 0.85 MDM2 (0.55) MDM2PDE4BPDE4DCNR2TP53
SCHEMBL1440032 0.80 MDM2 (0.62) MDM2PDE4BPDE4DTP53MAPT
SCHEMBL9894039 0.80 MDM2 (0.62) MDM2PDE4BPDE4DTP53MAPT
SCHEMBL28799416 0.79 MDM2 (0.49) MDM2PDE4BPDE4DCNR2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885PDE4B 3755/4885PDE4D 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.